Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    66.7%

    Based on 2 completed trials

    Completion Rate
    67%(2/3)
    Active Trials
    0(0%)
    Results Posted
    50%(1 trials)
    Terminated
    1(33%)

    Phase Distribution

    Phase 1
    1
    33%
    Phase 2
    2
    67%

    Phase Distribution

    1

    Early Stage

    2

    Mid Stage

    0

    Late Stage

    Phase Distribution3 total trials
    Phase 1Safety & dosage
    1(33.3%)
    Phase 2Efficacy & side effects
    2(66.7%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    66.7%

    2 of 3 finished

    Non-Completion Rate

    33.3%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Completed(2)
    Terminated(1)

    Detailed Status

    Completed2
    Terminated1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    0
    Success Rate
    66.7%
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 11 (33.3%)
    Phase 22 (66.7%)

    Trials by Status

    completed267%
    terminated133%

    Recent Activity

    0 active trials
    Showing 3 of 3
    completedphase_2

    A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica

    NCT03698864
    terminatedphase_2

    A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

    NCT04800562
    completedphase_1

    Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects

    NCT03836222

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT03698864Phase 2

    A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica

    Completed
    NCT04800562Phase 2

    A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

    Terminated
    NCT03836222Phase 1

    Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects

    Completed

    All 3 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    3